ABT-418

Source: Wikipedia, the free encyclopedia.
ABT-418
Identifiers
  • 3-Methyl-5-[(2S)-1-methylpyrrolidin-2-yl]-1,2-oxazole
JSmol)
  • CC1=NOC(=C1)[C@@H]2CCCN2C
  • InChI=1S/C9H14N2O/c1-7-6-9(12-10-7)8-4-3-5-11(8)2/h6,8H,3-5H2,1-2H3/t8-/m0/s1 checkY
  • Key:ILLGYRJAYAAAEW-QMMMGPOBSA-N checkY
 ☒NcheckY (what is this?)  (verify)

ABT-418 is a drug developed by

α3β4 receptors[10][11][12] ABT-418 was reasonably effective for both applications and fairly well tolerated, but produced some side effects, principally nausea, and it is unclear whether ABT-418 itself will proceed to clinical development or if another similar drug will be used instead.[13]

See also

References

  1. PMID 7518514
    .
  2. PMID 7913497
    .
  3. PMID 7965735
    .
  4. S2CID 34377165
    .
  5. PMID 20932609
    .
  6. S2CID 27337634
    .
  7. S2CID 20375475
    .
  8. S2CID 41914443
    .
  9. S2CID 26801069
    .
  10. PMID 9031746
    .
  11. PMID 20932609
    .
  12. S2CID 54338489
    .
  13. PMID 17689498
    .
Retrieved from "https://en.wikipedia.org/w/index.php?title=ABT-418&oldid=1205243647"